CAMBRIDGE, Mass., June 16, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that the Company concluded a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) related to its investigational drug candidate, lomitapide, for the treatment of homozygous familial hypercholesterolemia (HoFH). Following the meeting, the Company said it intends to proceed with its NDA submission as previously announced.
